Advertisement

Advertisement

ALKS Stock Latest News

Alkermes to present new data on Alixorexton, LUMRYZ

The FlyAlkermes to present new data on Alixorexton, LUMRYZ

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

PremiumRatings

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

7d ago

Alkermes Shareholders Approve Amended Stock Incentive Plan

PremiumCompany Announcements

Alkermes Shareholders Approve Amended Stock Incentive Plan

15d ago

Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge

PremiumCompany Announcements

Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge

16d ago

Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline

PremiumCompany Announcements

Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline

20d ago

Alkermes price target raised to $48 from $45 at Baird

PremiumThe FlyAlkermes price target raised to $48 from $45 at Baird

22d ago

Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study

The Fly

Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study

23d ago

Alkermes Reports Positive Phase 3 Results for LUMRYZ

Company Announcements

Alkermes Reports Positive Phase 3 Results for LUMRYZ

23d ago

Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market

PremiumCompany Announcements

Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market

28d ago

Alkermes price target raised to $48 from $42 at UBS

PremiumThe Fly

Alkermes price target raised to $48 from $42 at UBS

28d ago

Alkermes price target raised to $50 from $45 at Needham

PremiumThe Fly

Alkermes price target raised to $50 from $45 at Needham

29d ago

Alkermes Earnings Call: LUMRYZ Momentum Drives Growth

PremiumCompany Announcements

Alkermes Earnings Call: LUMRYZ Momentum Drives Growth

30d ago

Alkermes reports Q1 EPS (40c) vs 13c last year

PremiumThe FlyAlkermes reports Q1 EPS (40c) vs 13c last year

1M ago

Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B

The Fly

Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B

1M ago

Alkermes plc (ALKS) Q1 Earnings Cheat Sheet

Pre-Earnings

Alkermes plc (ALKS) Q1 Earnings Cheat Sheet

1M ago

Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating

PremiumRatings

Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating

2M ago

Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study

PremiumThe Fly

Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study

2M ago

Alkermes announces publication of 56-week post hoc analysis of Lybalvi

PremiumThe Fly

Alkermes announces publication of 56-week post hoc analysis of Lybalvi

2M ago

Alkermes price target raised to $36 from $34 at BofA

PremiumThe Fly

Alkermes price target raised to $36 from $34 at BofA

2M ago

Alkermes price target lowered to $44 from $45 at RBC Capital

PremiumThe FlyAlkermes price target lowered to $44 from $45 at RBC Capital

2M ago

Alkermes management to meet with Piper Sandler

The Fly

Alkermes management to meet with Piper Sandler

2M ago

Alkermes announces initiation of Brilliance Studies

The Fly

Alkermes announces initiation of Brilliance Studies

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >